RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $521,057 | +6.2% | 68,112 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $490,704 | +11.5% | 65,690 | -0.4% | 0.00% | 0.0% |
| Q1 2023 | $439,927 | -11.7% | 65,956 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $498,413 | -27.8% | 64,645 | -0.4% | 0.00% | -40.0% |
| Q3 2022 | $690,000 | +34.0% | 64,880 | +2.5% | 0.01% | +66.7% |
| Q2 2022 | $515,000 | +25.6% | 63,291 | +10.6% | 0.00% | +50.0% |
| Q1 2022 | $410,000 | -60.9% | 57,225 | -6.6% | 0.00% | -60.0% |
| Q4 2021 | $1,049,000 | +196.3% | 61,251 | +297.7% | 0.01% | +150.0% |
| Q3 2021 | $354,000 | -18.1% | 15,400 | +30.1% | 0.00% | +100.0% |
| Q2 2021 | $432,000 | – | 11,839 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $79,603,360 | 100.00% |
| Data Collective IV GP, LLC | 5,941,120 | $45,449,568 | 43.00% |
| MIC Capital Management UK LLP | 8,451,758 | $64,655,952 | 14.74% |
| MV Management XI, L.L.C. | 788,762 | $6,034,029 | 10.04% |
| ArchPoint Investors | 1,047,386 | $8,012,503 | 3.06% |
| Connective Portfolio Management, LLC | 33,000 | $252,000 | 0.77% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,335,132 | $17,863,760 | 0.70% |
| Diametric Capital, LP | 136,331 | $1,042,932 | 0.44% |
| ARK Investment Management | 6,876,598 | $52,605,973 | 0.40% |
| ALLEN OPERATIONS LLC | 217,657 | $1,665,076 | 0.37% |